It’s only fair to share… Sonrotoclax CAS 2383086-06-2 MW 890.1 g/mol, MFC49H59N7O7S FDA APPROVED 5/13/2026, Beqalzi, APPROVALS 2026, BGB-11417, BGB 11417, 30R67U9KYS N-[4-[(4-hydroxy-4-methylcyclohexyl)methylamino]-3-nitrophenyl]sulfonyl-4-[2-[(2S)-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective …
Category «FDA 2026,»
Navepegritide
It’s only fair to share… Navepegritide Cas 2413551-27-4 Molecular Formula: C₂₃₁H₃₈₆N₆₄O₆₇S₅ + (C₂H₄O)₄ₙ (approx. 45 kDa), 1804.0 g/mol MOLECULAR FORMULA C231H386N64O67S5 + (C2H4O)4nMOLECULAR WEIGHT approx. 45 kDa The structure of navepegritide (YUVIWEL®) is built using a “prodrug” design. It is not a simple small molecule, but rather a complex conjugate consisting of three distinct components designed to release the active …
Milsaperidone
It’s only fair to share… Milsaperidone CAS 501373-88-2 C24H29FN2O4 MW 428.50 FDA APPROVED 2/20/2026, Bysanti, To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder (1S)-1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanol 7SV1ZOG031, P-88-8991, (-)-, (S)-Hydroxy Iloperidone, P-88, VHX 869, VHX-896 Milsaperidone (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), also known by its developmental code name VHX-896 and …
Baxdrostat
It’s only fair to share… Baxdrostat cas 1428652-17-8 APPROVALS 2026, FDA 2026, 5/15/2026, Baxfendy To treat hypertension in combination with other antihypertensive drugs WeightAverage: 363.461Monoisotopic: 363.194677057 Chemical FormulaC22H25N3O2 N-[(8R)-4-(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide Baxdrostat is an investigational drug that is being evaluated for the treatment of hypertension.[1] It is an aldosterone synthase inhibitor.[2][3] Baxdrostat is under investigation in clinical trial NCT06344104 (A Phase III Study to …
Difamilast
It’s only fair to share… Difamilast FDA 2026, APPROVALS 2026, difamilast, Adquey, 2/12/2026, To treat mild to moderate atopic dermatitis PMDA Moizerto, JAPAN APPROVED 2021/9/27 ジファミラスト ディファミラスト; 地法米司特 N-({2-[4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl]-1,3- oxazol-4-yl}methyl)-2-ethoxybenzamide OPA-15406 Formula C23H24F2N2O5 CAS 937782-05-3 Mol weight 446.4439 MM 36; MM-36-Medimetriks-Pharmaceuticals; Moizerto; OPA-15406 Efficacy Anti-inflammatory, Phosphodiesterase IV inhibitor Comment Treatment of atopic dermatitis OriginatorOtsuka Pharmaceutical Development …